Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-035893
Filing Date
2024-08-08
Accepted
2024-08-08 08:26:47
Documents
64
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q prme-20240630.htm   iXBRL 10-Q 917175
2 EX-10.1 q22024ex101-amendeddirecto.htm EX-10.1 21336
3 EX-31.1 q22024ex311.htm EX-31.1 12038
4 EX-31.2 q22024ex312.htm EX-31.2 12222
5 EX-32.1 q22024ex321.htm EX-32.1 7455
6 EX-32.2 q22024ex322.htm EX-32.2 7458
  Complete submission text file 0001628280-24-035893.txt   5040873

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20240630.xsd EX-101.SCH 36292
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prme-20240630_cal.xml EX-101.CAL 58109
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prme-20240630_def.xml EX-101.DEF 211348
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20240630_lab.xml EX-101.LAB 429882
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20240630_pre.xml EX-101.PRE 316104
66 EXTRACTED XBRL INSTANCE DOCUMENT prme-20240630_htm.xml XML 641392
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41536 | Film No.: 241186218
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)